Slingshot members are tracking this event:
Agios Pharma (AGIO) to complete Phase 1 study of AG-120 in subjects With Advanced Hematologic Malignancies With an IDH1 Mutation in September 2017
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Jun 03, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 1 Study, Ag-120, Hematologic Malignancies, Acute Myeloid Leukemia, Idh1 Mutation, Open-label